Idorsia Ltd. IDIA
SIX · Switzerland · Health Technology
CHF 4.64-0.01 (-0.13%)
Market open· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
BioPharma Credit (LON:BPCP) reported a higher share price and continued portfolio diversification in its half-year investor presentation, while manager Pharmakon said it is managing cash to support new lending opportunities and potential future repayments. Pedro Gonzalez de Cosio, chief executive o
Idorsia (SWX:IDIA) continues to attract attention after recent share price moves, with the stock down 4.5% on the latest trading day and showing weaker performance over the past month and the past three months. Short term momentum for Idorsia looks weak, with the share price falling 11% over the past week and 22% over the past month. However, the year to date share price return of 7% and 1-year total shareholder return of 17% suggest the longer term picture has been more supportive. Spot...
Idorsia has given investors a wild ride over the past few years, and the big question now is whether the current share price can be squared with the revenue the business is generating. With the stock having gone through both sharp gains and deep declines, the issue is how much of its sales power is already baked into today's valuation. Over the last 5 years the share price has fallen 79.8%, which puts the spotlight firmly on whether the revenue base can support where the stock now...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.